Next-generation probiotics (NGPs) contain microorganisms, most of which are bacteria similar to the beneficial ones that naturally occur in the human gut. They differ from conventional probiotics since their application goes beyond food or dietary supplements and are exploited in pharmaceutical areas to treat gastrointestinal (GI) disorders as well as many other diseases.

Owing to the dramatic promise of NGPs as a treatment modality for GI diseases such as inflammatory bowel diseases (IBD), Clostridium difficile infection (CDI), ulcerative colitis (UC), and pouchitis, the world-leading CRO Creative Biolabs has conducted a thorough investigation into their mechanisms of action and made a series of solutions associated with NGP development available.

On the whole, NGPs exert therapeutic influence on GI distress by means of direct interaction with immune cells, which plays a significant role in maintaining immunologic equilibrium in the gastrointestinal tract. When diving into details, their mechanisms of action seem fairly complex and may vary among different bacteria species. The common mechanisms are concluded as follows:
*Block the adhesion of pathogenic bacteria to the intestinal epithelium; produce inhibitory agents;
*Enhance the intestinal immune response;
*Maintain normal levels of short-chain fatty acids;
*Modulate immune system function, such as suppression of intestinal pro-inflammatory cytokines;
*Repair intestinal permeability;
*Suppress the growth of pathogenic bacteria by directly binding to gram-negative bacteria;
*Upregulate intestinal electrolyte absorption.

The case study of NGP application in inflammatory bowel disease (IBD) is a potent indication of how NGPs act on GI disorders. In contrast to traditional tactics based on pharmacological methods to mitigate inflammation and control disease relapse, NGP administration that is in pursuit of re-establishing microbial balance presents unrivaled strengths in inducing anti-inflammatory effects and enhancing (or repairing) barrier function. Besides, NGPs could suppress the rise of harmful bacteria and facilitate the growth of beneficial ones, thus altering the composition of the microbiome and finally achieving success in IBD treatment.

An overall understanding of the NGP action mechanism is merely the first move towards final live biotherapeutic drug discovery. On the basis of comprehensive studies about NGPs, the top-ranking biotech company Creative Biolabs provides not only one-stop but also stand-alone NGP development services for pharmaceutical manufacturers. To be specific, the whole process of NGP production originating from strain identification, validation, analysis, and qualification, to eventual cGMP manufacturing can be entirely entrusted to Creative Biolabs. Meanwhile, if it is only a small portion of the procedures requiring technical aid, Creative Biolabs is also the trustworthy assistant for manufacturers' NGP projects.

Researchers have invested much energy in NGP development which opens up the door of novel clinical therapeutics. Nowadays, the application of NGPs as an alternative therapeutic approach gradually extends to many disease types such as gastrointestinal disorders, metabolic disease, and cancers, raising it to be a revolutionary breakthrough in biopharmaceutical research.

Author's Bio: 

A big fan of biotech!